Skip to main content
SpringerLink
Log in

Bevacizumab/paclitaxel

Haematological toxicity: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Valery SC, et al. Efficacy of weekly paclitaxel-bevacizumab combination in advanced non squamous non-small cell lung cancer (NSCLC) progressing after immune checkpoint inhibitors -AVATAX , a retrospective multicentric study: Preliminary data. Annals of Oncology 30 (Suppl. 11): xi29 abstr. 81P, Dec 2019. Available from: URL: https://doi.org/10.1093/annonc/mdz449.035 [abstract]

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab/paclitaxel. Reactions Weekly 1791, 50 (2020). https://doi.org/10.1007/s40278-020-74895-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-74895-1

Search

Navigation